Eskens, F., Mom, C.H., Planting, A.S.T., Gietema, J.A., Amelsberg, A., Huisman, H., ...
To assess tolerability, pharmacokinetics ( PK), pharmacodynamics ( PD) and clinical activity of the dual epidermal growth factor receptor ( EGFR) 1 and 2 ( HER2) tyrosine kinase inhibitor BIBW 2992....
Eskens, F., Mom, C.H., Planting, A.S.T., Gietema, J.A., Amelsberg, A., Huisman, H., ...
To assess tolerability, pharmacokinetics ( PK), pharmacodynamics ( PD) and clinical activity of the dual epidermal growth factor receptor ( EGFR) 1 and 2 ( HER2) tyrosine kinase inhibitor BIBW 2992....
Perik, P. J., Rikhof, B., De Jong, F. A., Verweij, J., Gietema, J. A.
Background: Recently, case reports of patients treated with imatinib (imatinib mesylate; Gleevec®; Glivec®) indicated that this tyrosine kinase inhibitor may induce cardiomyopathy. Consequently,...
Although single-target agents have been shown to improve patient outcomes in certain tumour types, drug resistance often occurs due to salvage pathways that compensate for the inhibited signalling...
Scott, L, Soepenberg, O, Verweij, J, De Jonge, MJA, Th Planting, AS, McGovern, D, ...
Background: BN80915 (diflomotecan) is an E-ring modified camptothecin analogue, which possesses greater lactone stability in plasma compared with other topoisomerase I inhibitors. This phase I study...
Verweij, J, Yarkoni, S, Snyder, D, Lacombe, D, ...
PURPOSE: Halofuginone (tempostatin) is a synthetic derivative of a quinazolinone alkaloid showing anti-angiogenic, anti-metastatic and anti-proliferative effects in preclinical studies. The...
What is the role of dose-dense therapy? (2005)
Burger, C W, Van Doorn, H C, De Wit, R, ...
The introduction of paclitaxel/platinum combination chemotherapy and (interval) debulking surgery has significantly improved the prognosis of patients with ovarian cancer. Yet, many patients die of...
Blay, J Y, Judson, I, Verweij, J, Radford, J, ...
PURPOSE: This nonrandomized multicenter phase II study was performed to evaluate the activity and safety of Ecteinascidin (ET-743) administered at a dose of 1.5 mg/m(2) as a 24-hour continuous...
Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors (2005)
Soepenberg, O., Jonge, M.J. De, Sparreboom, A., Bruin, P. De, Eskens, F.A., Heus, G. De, ...
PURPOSE: To assess the maximum-tolerated dose, toxicity, and pharmacokinetics of DE-310, a macromolecular prodrug of the topoisomerase I inhibitor exatecan (DX-8951f). in patients with advanced solid...
What is the role of dose-dense therapy? (2005)
Vergote, Ignace; U0002443, Burger, C, Van Doorn, H, De Wit, R, ...
Van Zuylen, L., Bridgewater, J., Sparreboom, A., De Bruijn, P., Sklenar, I., ...
Purpose: The purpose of our study was to determine the maximum-tolerated dose, dose-limiting toxicity, safety profile, and pharmacokinetics of the polyamine synthesis inhibitor SAM486A given in...
Judson, I, Verweij, J, Brown, M, ...
Previous studies have shown that activating mutations of c-KIT/PDGFRA, potential therapeutic targets for imatinib mesylate, are implicated in the pathophysiology of gastrointestinal stromal tumours...
Polee, M.B., Sparreboom, A., Eskens, F.A., Hoekstra, R., Schaaf, J. Van De, Verweij, J., ...
PURPOSE: To determine the maximum-tolerated dose, toxicity profile, and pharmacokinetics of a fixed dose of paclitaxel followed by increasing doses of carboplatin, given weekly to patients with...
Zuylen, L. Van, Mueller, C., Verweij, J., Ledermann, J.A., Bridgewater, J., Sparreboom, A., ...
PURPOSE: The purpose of our study was to determine the maximum-tolerated dose, dose-limiting toxicity, safety profile, and pharmacokinetics of the polyamine synthesis inhibitor SAM486A given in...
Sparreboom, A., Wolff, A.C., Verweij, J., Zabelina, Y., Zomereen, D.M. Van, McIntire, G.L., ...
PURPOSE: Docosahexaenoic acid-paclitaxel is as an inert prodrug composed of the natural fatty acid DHA covalently linked to the C2'-position of paclitaxel (M. O. Bradley et al., Clin. Cancer Res., 7:...
Ten Tije, A.J., Antonellini, A., Mantel, M., Jonge, M.J., Hartman, C.M., Planting, A.S., ...
PURPOSE: Brostallicin (PNU-166196) is a cytotoxic agent that binds to the minor groove of DNA with significant antitumor activity in preclinical studies. This trial was designed to determine the...
Irinotecan pathway genotype analysis to predict pharmacokinetics (2003)
Mathijssen, R.H., Marsh, S., Karlsson, M.O., Xie, R., Baker, S.D., Verweij, J., ...
PURPOSE: The purpose was to explore the relationships between irinotecan disposition and allelic variants of genes coding for adenosine triphosphate binding cassette transporters and enzymes of...
Gelderblom, H., Prunonosa, J., Twelves, C., Principe, P., Salazar, R., Verweij, J., ...
PURPOSE: Diflomotecan (BN80915) is an E-ring modified camptothecin analogue that possesses greater lactone stability in plasma compared with other topoisomerase I inhibitors, a potential advantage...
Louwerens, M, Pawinsky, A, Planting, A S Th, Van Oosterom, A T, ...
Our objective was to determine the maximum tolerated dose (MTD) of two administration sequences of docetaxel and gemcitabine in cancer patients, and to describe the pharmacokinetics of both drugs....
Loos, W.J., Verweij, J., Kehrer, D.F., Bruijn, P. De, Groot, F.M. De, Hamilton, M., ...
An additional chromatographic peak was observed in plasma samples of patients receiving NX 211, a liposomal formulation of the topoisomerase I inhibitor lurtotecan. We have isolated and purified this...
Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel (2002)
Gelderblom, H., Verweij, J., Zomeren, D.M., Buijs, D., Ouwens, L., Nooter, K., ...
It has been hypothesized that the paclitaxel vehicle Cremophor EL (CrEL) is responsible for nonlinear drug disposition by micellar entrapment. To gain further insight into the role of CrEL in taxane...
Effects of St. John's wort on irinotecan metabolism (2002)
Mathijssen, R.H., Verweij, J., Bruijn, P. De, Loos, W.J., Sparreboom, A.
St. John's wort (SJW), a widely used herbal product, has been implicated in drug interactions resulting from the induced expression of the cytochrome P450 CYP3A4 isoform. In this study, we determined...
Judson, I, Verweij, J, Dimitrijevic, S, ...
BACKGROUND: Gastrointestinal stromal tumours (GISTs) are rare tumours of the gastrointestinal tract characterised by cell-surface expression of the tyrosine kinase KIT (CD117). No effective systemic...
Planting, AST, Ma, J, Maliepaard, M, Dennert, MD, ...
The purpose of this study was to explore the feasibility and toxicity of intrapatient dose adjustment using predefined levels of exposure to cisplatin, with the ultimate goal to further improve the...
Characterization and use of a digital light projector for vision research. (2001)
Packer, O., Diller, L. C., Verweij, J., Lee, B. B., Pokorny, J., Williams, D. R., ...
Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients (2001)
Kehrer, D.F., Sparreboom, A., Verweij, J., Bruijn, P. De, Nierop, C.A., Schraaf, J. Van De, ...
This study was designed to evaluate irinotecan (CPT-11) disposition and pharmacodynamics in the presence and absence of the broad-spectrum antibiotic neomycin. Seven evaluable cancer patients...
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) (2001)
Mathijssen, R.H., Alphen, R.J. Van, Verweij, J., Loos, W.J., Nooter, K., Stoter, G., ...
CPT-11 belongs to the class of topoisomerase I inhibitors, and it acts as a prodrug of SN-38, which is approximately 100-1000-fold more cytotoxic than the parent drug. CPT-11 has shown a broad...
Matrix metalloproteinase inhibitors: current developments and future perspectives (2001)
Hoekstra, R., Eskens, F.A., Verweij, J.
Malignant tumors are characterized by invasive growth and metastasis. To facilitate this invasive behavior, the enzymatic breakdown of the extracellular matrix (ECM) is a prerequisite. Many human...
Judson, I, Crowther, D, Rodenhuis, S, Keizer, H J, Van Hoesel, Q, ...
PURPOSE: This randomized multicenter study was designed to compare the activity of a high-dose doxorubicin-containing chemotherapy regimen with a conventional standard-dose regimen in adult patients...
Aamdal, S, Awada, A, Calvert, H, Fumoleau, P, Sorio, R, ...
PURPOSE: In a phase II trial, the activity of carzelesin, a cyclopropylpyrroloindole prodrug analog, was assessed. PATIENTS AND METHODS: Carzelesin was used as second- or third-line chemotherapy in...
Judson, I, Van Hoesel, Q, Le Cesne, A, Keizer, H J, Blay, J Y, ...
In this phase II study the effect of high-dose ifosfamide (HDI) given as a 3-day continuous infusion at a dose of 12 g/m2 repeated every 4 weeks with adequate mesna protection and hydration was...
Eskens, F.A., Levitt, N.C., Sparreboom, A., Choi, L., Mather, R., Verweij, J., ...
MMI270B is a matrix metalloproteinase inhibitor (MMPI) with in vitro and in vivo activity. To exert optimal target inhibition, MMPI must be given chronically, and therefore, oral bioavailability is...
Topotecan lacks third space sequestration (2000)
Gelderblom, H., Loos, W.J., Verweij, J., Jonge, M.J. De, Sparreboom, A.
The objective of this study was to determine the influence of pleural and ascitic fluid on the pharmacokinetics of the antitumor camptothecin derivative topotecan. Four patients with histological...
Zuylen, L. Van, Sparreboom, A., Gaast, A. Van Der, Beurden, V. Van, Bol, C.J., ...
This Phase I study was performed to assess the feasibility of combining docetaxel with the new P-glycoprotein inhibitor R101933 and to determine the dose limiting toxicity of this combination....
Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans (2000)
Zuylen, L. Van, Verweij, J., Nooter, K., Brouwer, E., Stoter, G., Sparreboom, A.
Multidrug resistance (MDR)-1-P-glycoprotein (P-gp) is a drug-transporting protein that is abundantly present in biliary ductal cells and epithelial cells lining the gastrointestinal tract. Here, we...
Loos, W.J., Gelderblom, H., Sparreboom, A., Verweij, J., Jonge, M.J. De
Anticancer drugs still are dosed based on the body-surface area (BSA) of the individual patient, although the BSA is not the main predictor of the clearance for the majority of drugs. The relevance...
Measurement of fraction unbound paclitaxel in human plasma (2000)
Brouwer, E., Verweij, J., Bruijn, P. De, Loos, W.J., Pillay, M., Buijs, D., ...
The clinical pharmacokinetic behavior of paclitaxel (Taxol) is distinctly nonlinear, with disproportional increases in systemic exposure with an increase in dose. We have recently shown that...
Kehrer, D.F., Yamamoto, W., Verweij, J., Jonge, M.J. De, Bruijn, P. De, Sparreboom, A.
The active metabolite of irinotecan (CPT-11), 7-ethyl-10-hydroxycamptothecin (SN-38), is either formed through enzymatic cleavage of CPT-11 by carboxyl esterases (CEs) or through cytochrome P-450...
Sparreboom, A., Zuylen, L. Van, Brouwer, E., Loos, W.J., Bruijn, P. De, Gelderblom, H., ...
We have determined the in vitro and in vivo cellular distribution of the antineoplastic agent paclitaxel (Taxol) in human blood and the influence of Cremophor EL (CrEL), the vehicle used for i.v....
Gerrits, C.J., Hudson, I., Verweij, J., Von Hoff, D.D., Schellens, J.H., Burris, H., ...
Prolonged exposure to topotecan in in vitro and in vivo experiments has yielded the highest antitumor efficacy. An oral formulation of topotecan with a bioavailability of 32-44% in humans enables...
Sparreboom, A., Jonge, M.J. De, Punt, C.J., Loos, W.J., Nooter, K., Stoter, G., ...
The purpose of this study was to develop and validate limited-sampling strategies for prediction of the area under the plasma-concentration time curves (AUCs) of the lactone and total (i. e., lactone...
Jonge, M.J. De, Verweij, J., Planting, A.S., Stoter, G., ...
In this study, 11 patients with solid tumors were randomized to receive irinotecan (CPT-11; 200 mg/m2) as a 90-min i.v. infusion, immediately followed by cisplatin (CDDP; 80 mg/m2) as a 3-h i.v....
Gelderblom, H., Verweij, J., Brouwer, E., Pillay, M., Bruijn, P. De, Nooter, K., ...
In the present work, we studied the pharmacokinetics and metabolic disposition of [G-(3)H]paclitaxel in a female patient with recurrent ovarian cancer and severe renal impairment (creatinine...
Schöffski, P., Catimel, G., Planting, A. S. T., Verweij, J., Schrijvers, D., ...
Background: Docetaxel and cisplatin are among the most active antitumor agents in head and neck cancer, and phase I studies found tne combination of the two drugs to be feasible. The EORTC ECSG...
Experience with independent radiological review during a topotecan trial in ovarian cancer (1997)
Gwythen, S., Bolis, G., Gore, M., Huinink, W. Ten Bokkel, Verweij, J., Hudson, I. R., ...
Background: The results of phase II clinical trials are usually based on response of tumours to new oncolytic agents as evidenced by radiological imaging techniques. In this trial, all claimed...
Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere) (1997)
Hilkens, P. H. E., Verweij, J., Vecht, Ch. J., Stoter, G., Van Den Bent, M. J.
Background: Docetaxel, a semi-synthetic taxane may cause a usually mild sensory neuropathy. We describe the clinical characteristics of five patients who developed a more severe neuropathy following...
De Vos, A. I., Nooter, K., Verweij, J., Loos, W. J., Brouwer, E., De Bruijn, P., ...
Background Several clinical studies have shown that polychemotherapy with the taxanes paclitaxel or docetaxel preceded or followed by cisplatin is associated with important schedule-dependent...
Halman, L., Pettersson, T., Verweij, J.
This paper explores the relationships between values in the religious domain and values in other societal spheres. Starting from the general idea that the impact of religion on other domains in life...
Multicentre phase II pharmacological evaluation of rhizoxin (1996)
Verweij, J., Aamdal, S., Wagener, D.J.T., Heinrich, B., Pavlidis, N., ...
Phase II study rhizoxin in squameus cell head and neck cancer (1996)
Catimel, G., Schöffski, P., Gil, Th., Wanders, J., ...
Cunningham, D., Dicato, M., Verweij, J., Crombez, R., De Mulder, P., Du Bois, A., ...
Background: This study was undertaken to compare the efficacy and tolerability of ondansetron plus dexamethasone (O+D) with metoclopramide plus dexamethasone plus lorazepam (M+D+L)...
Pavlidis, N., Hanauske, A. R., Gamucci, T., Smyth, J., Lehnert, M., Velde, A. Te, ...
In a multicentre randomized trial of the EORTC-ECSG, we have treated 38 chemotherapy naïve patients with advanced non-small-cell lung cancer (NSCLC) with EO9, a novel bio-reductive alkylating...
Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck (1996)
Verweij, J., De Graeff, A., Vermorken, J. B., Wildier, J., Kerger, J., ...
Background: Based on activity in a case report, mitoxantrone was studied in a phase II study in adenoid cystic carcinoma. Patients and methods: Patients with symptomatic and/or rapidly...
Planting, A. S. T., De Wit, R., Stoter, G., Verweij, J.
Background: Ifosfamide and cisplatin are frequently combined cytotoxic agents. Both have a dose-response relationship. In view of this it appears attractive to study regimens with a higher dose...
Phase II clinical trials with rhizoxin in breast cancer and melanoma (1996)
Catimel, G., Aamdal, S., Pavlidis, N., ...
Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer (1995)
Gore, M, Verweij, J, Wanders, J, ...
BACKGROUND: Because of the relative scarcity of natural paclitaxel (Taxol), which has been recently recognized as a highly cytotoxic agent for use in platinum-refractory ovarian cancer, synthetic and...
On the Deposition Kinetics of the LPCVD Gate Oxides Prepared from SiH4 and O2 (1995)
Rem, J., Klootwijk, J., Cobianu, C., Holleman, J., Verweij, J.
An experimental study on the deposition kinetics of LPCVD SiO2 films at 450°C in a hot wall system from SiH4 and O2 in the range of very high O2 / SiH4 ratios (100-284) and very low SiH4 partial...
Phase II studies of docetaxel in the treatment of various solid tumours (1995)
Aamdal, S., Wolff, I., Sternberg, C.N., Sulkes, A., Catimel, G., ...
On the Deposition Kinetics of the LPCVD Gate Oxides Prepared from SiH4 and O2 (1995)
Rem, J., Klootwijk, J., Cobianu, C., Holleman, J., Verweij, J.
An experimental study on the deposition kinetics of LPCVD SiO2 films at 450°C in a hot wall system from SiH4 and O2 in the range of very high O2 / SiH4 ratios (100-284) and very low SiH4 partial...
On the Deposition Kinetics of the LPCVD Gate Oxides Prepared from SiH4 and O2 (1995)
Rem, J., Klootwijk, J., Cobianu, C., Holleman, J., Verweij, J.
An experimental study on the deposition kinetics of LPCVD SiO2 films at 450°C in a hot wall system from SiH4 and O2 in the range of very high O2 / SiH4 ratios (100-284) and very low SiH4 partial...
Planting, A. S. T., Goey, S. H., ScheUens, J. H. M., Van Den Bent, M. J., ...
Background In a previous phase II study with a dose-intensive weekly cisplatin schedule for six cycles, we observed a partial response in 5 of 14 patients with pleural mesothelioma. However, response...
Wagener, D. J. Th., Verdonk, H. E. R., Dirix, L. Y., Catimel, G., Siegenthaler, P., Buitenhuis, M., ...
Background CPT-11 (irinotecan) is a semi-synthetic derivative of camptothecin and exerts its activity by inhibiting DNA topoisomerase I. A phase II study of this drug was performed in patients with...
Planting, A. S. T., Stoter, G., Verweij, J.
Background In a previous phase I study we showed that single-agent cisplatin can be given weekly for six weeks at a dose of 80 mg/m2/wk. It has been suggested that etoposide has synergistic...
Topotecan in colorectal cancer: A phase II study of the EORTC early clinical trials group (1995)
Creemers, G. J., Wanders, J., Vallentin, S., Dirix, L. Y., Schöffski, P., ...
Background: This phase II study with the topoisomerase I inhibitor topotecan was performed to determine its clinical activity and toxicity in patients with metastatic or locally unresectable...
Sessa, C., Aamdal, S., Wolff, I., Eppelbaum, R., Smyth, J. F., Sulkes, A., ...
Background: Gemcitabine is a water-soluble analogue of deoxycytidine which has shown significant antitumour activity in a broal panel of slow-growing murine and human carcinomas. Objective responses...
Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): Not simply two of a kind (1994)
Verweij, J., Clavel, M., Chevalier, B.
Paclitaxel and docetaxel are the two presently clinically available representatives of the new class of taxane drugs. They share major parts of their structures and mechanisms of action, but differ...
Clavel, M., Vermorken, J. B., Cognetti, F., Cappelaere, P., Schornagel, J. H., ...
Background The EORTC Head and Neck Cancer Cooperative Group conducted a randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF)...
Ten Bokkel Huinink, W. W., Prove, A. M., Piccart, M., Steward, W., Tursz, T., Wanders, J., ...
Background Docetaxel, a semisynthetic analog of paclitaxel, made for the needles of the European yew, Taxus baccata, is a potentially important chemotherapeutic agent for the treatment of cancer....
Catimel, G., Verweij, J., Mattijssen, V., Hanauske, A., Piccart, M., Wanders, J., ...
Background Docetaxel (Taxotere®) is a new cytotoxic agent acting as a promotor of tubulin polymerisation with broad spectrum antitumor activity in preclinical testing. Phase I clinical trials have...
Phase II study with Docetaxel (Taxotere(R)) in advanced soft tissue sarcomas of the adult (1994)
Verweij, J., Catimel, G., Clavel, M., Kerbrat, P., Oosterom, A. T.van, ...
Background Current regimens for treatment of distant metastases of soft tissue sarcomas result in response rates of about 25%. Therefore the search for active drugs remains a task for...
Catimel, G., Vermorken, J. B., Clavel, M., De Mulder, P., Judson, I., Sessa, C., ...
Background Gemcitabine is a new pyrimidine antimetabolite with novel metabolic properties and mechanism of action. Phase I clinical trials have demonstrated acceptable toxicity and promising...
Limited sampling models for topotecan pharmacokinetics (1994)
Verweij, J., Rosing, H., Schellens, J. H. M., Maes, R. A. A., Beijnen, J. H.
Background Limited sampling models for the estimation of the topotecan Area Under the concentration versus time Curve (AUC) and its lactone ring opened form (AUC Tm), from one or more plasma...
Weekly high-dose cisplatin in malignant pleural mesothelioma (1994)
Planting, A. S. T., Schellens, J. H. M., Goey, S. H., Stoter, G., ...
Background: Cisplatin at conventional doses has marginal activity in mesothelioma. A dose-response relation for cisplatin has been suggested in other tumor types. In a phase I study on weekly...
Verweij, J., Wanders, J., Nielsen, A. L., Pavlidis, N., Calabresi, F., Huinink, W. Ten Bokkel, ...
Purpose: To test the antitumor activity of Elsamitrucin in metastatic cancer of the breast, colon and rectum, non-small cell lung and ovary. Patients and methods: Eligibility required histologically...
De Wit, R., Gaast, A. V.d., Logmans, A., Stoter, G., Verweij, J.
Patients and methods: Twenty-eight patients with ovarian cancer refractory to or relapsing within 12 months after cis-platin-containing chemotherapy were treated with etoposide 50 mg/m2 daily for...
(R)-2-Phenylglycine as a Chiral Auxiliary in the Asymmetric Synthesis of 2-Azetidinones (1993)
Koten, G. Van, Maanen, H.L. Van, Verweij, J., Kieboom, A.P.G., Spek, A.L.
The chlorozinc enolate of ethyl-[(2, 2,5,5-tetramethyl-1-aza-2,5-disila)cyclopentyl]-acetate was reacted with the ZnCl{2} complex of N-benzylidene-2-phenylglycine methyl ester in THF at -70 }o{C....
Vermorken, J. B., Verweij, J., Cognetti, F., Clavel, M., Rodenhuis, S., ...
Background: Because of the rarity of salivary gland cancer, little is known about the single-agent activity of most anticancer agents in the different histologic types of these cancers. Patients and...
Henzen-Logmans, S. C., Th Planting, A. S., Stoter, G., Verweij, J.
Background: The prognosis of patients with well- and moderately-differentiated adenocarcinomas of unknown primary is poor, as a consequence of chemotherapy resistance. Patients and methods: We...
Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor (1993)
Verweij, J., Lund, B., Beijnen, J., Koier, I., Rosing, H., ...
Purpose: A phase I study with topotecan (SKF 104864-A, NSC 609699), a semisynthetdc analog of camptothecin, was performed using a daily-times-5 regimen, given i.v. q 3 weeks, to evaluate the...
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group (1992)
Steward, W P, Verweij, J, Mouridsen, H, Bramwell, V, Schütte, J, ...
The Soft Tissue and Bone Sarcoma Group of the European Organization on Research and Treatment of Cancer has conducted a number of studies of chemotherapy in advanced disease over the past 15 years....
Kaye, S. B., Wanders, J., Clavel, M., Verweij, J., Piccart, M. J., Smyth, J. F., ...
A total of 91 eligible patients with metastatic cancer have been treated in a series of phase II trials of the novel pentacyclic pyrroloquinone, fosquidone. Tumour types were breast (24), ovary (25),...
Schornagel, J. H., Verweij, J., De Graeff, A., Dullemond-Westland, A., Van Deijk, W. A., ...
A phase II trial of the new antifolate edatrexate (10-ethyl-10-deaza-aminopterin) was performed in thirty-eight patients with metastatic breast cancer who had never received chemotherapy. Edatrexate...
Schornagel, J. H., Verweij, J., Cognetti, F., Vermorken, J. B., ...
Forty-seven patients with advanced and/or recurrent squamous cell carcinoma of the head and neck were treated with 10-ethyl-10-deaza-aminopterin (10-EdAM), a new analogue of methotrexate. The...
Frequent administration of Dabis Maleate, a phase I study (1992)
Verweij, J., Planting, A. S. Th., Boer, M. De, Stoter, G.
Dabis Maleate (l, 4-bis(2'-chloroethyl)-l, 4-diaza-bicyclo(2.2.1] Heptane dihydrogen dimaleate) (NSC 262666) is an alkylating quaternary nitrogen compound. In a previous phase I study using a...
Steward, W, Blackledge, G, Verweij, J
In multicentre studies, non-compliance with the protocol may limit the chances of reaching a correct conclusion. A procedure to examine the administration of chemotherapy in multicentre EORTC...
High-dose DTIC in advanced soft-tissue sarcomas in the adult (1991)
SYLVESTER, Richard, Buesa, J.M., Mouridsen, H.T., Van Oosterom, A.T., Verweij, J., Wagener, T., ...
High-dose DTIC in advanced soft-tissue sarcomas in the adult (1991)
Buesa, J.M., Mouridsen, H.T., Van Oosterom, A.T., Verweij, J., Wagener, T., Steward, W., ...
Forty-four of 50 adult patients with advanced soft-tissue sarcoma who had received previous chemotherapy were evaluable for response after treatment with DTIC. The therapeutic schedule consisted of...
Short report: Phase II study of ACNU as first-line treatment in advanced colorectal cancer (1991)
Planting, A., Hoff, A., Verweij, J., Stoter, G.
Thirty-two patients with metastatic colorectal cancer were entered in a phase II study of ACNU as first-line treatment. ACNU was given at a dose of 100 mg/m2 i.v. every six weeks. In 30 evaluable...
Buesa, J. M., Mouridsen, H. T., Van Oosterom, A. T., Verweij, J., Wagener, T., Steward, W., ...
Forty-four of 50 adult patients with advanced soft-tissue sarcoma who had received previous chemotherapy were evaluable for response after treatment with DTIC. The therapeutic schedule consisted of...
Verweij, J., Planting, A. S. Th., Gaast, A. V.d., Stoter, G.
A phase II study with cisplatin plus 24-hour infusion of ifosfamide (with mesna uroprotection) was performed in patients with metastatic malignant melanoma. The overall response rate was 40%...
The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer (1990)
The role of CA 125 determination in diagnosing progression of ovarian cancer was evluated in 98 patients of whom forty-nine had progressive disease. An elevated CA 125 level at the time of...
Original article: Carcinoma of unknown primary: Identification of a treatable subset? (1990)
Van Gaast, A. Der, Verweij, J., Henzen-Logmans, S.C., Rodenburg, C.J., Stoter, G.
We initiated a phase II study with combination chemotheraphy consisting of cisplatin, etoposide and bleomycin in a subset of patients with carcinomas of unknown primary site characterized by the...
Verweij, J, Fuchs, R, Keizer, H J, Somers, R, Rankin, E, ...
Department of Medicine, Queen Elizabeth Hospital, Edgbaston, Birmingham, U.K.
Mouridsen, H T, Bramwell, V, Santoro, A, Verweij, J, ...
West Midlands CRC Clinical Trials Unit, Queen Elizabeth Hospital, Birmingham, UK.
Strongyloides stercoralis associated with a bleeding gastric ulcer.
Dees, A, Batenburg, P L, Umar, H M, Menon, R S, Verweij, J
Infection with the helminthic parasite, Strongyloides stercoralis, is usually acquired by skin invasion (or occasionally via ingestion of larvae). After transformation to the adult form, the parasite...
Halman, L., Pettersson, T., Verweij, J.
This paper explores the relationships between values in the religious domain and values in other societal spheres. Starting from the general idea that the impact of religion on other domains in life...
Oral piritrexim, an effective treatment for metastatic urothelial cancer.
De Wit, R., Kaye, S. B., Roberts, J. T., Stoter, G., Scott, J., Verweij, J.
Piritrexim is a lipid-soluble inhibitor of dihydrofolate reductase (DHFR) that enters tumour cells rapidly by passive diffusion, cannot be polyglutamated, and is as effective as methotrexate in...
Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.
Planting, A. S., Van Der Burg, M. E., Stoter, G., Verweij, J.
Twenty-five patients with advanced solid tumours were entered in a phase I/II study of six, weekly cycles of cisplatin. Nineteen patients were chemonaive and six were previously treated. The starting...
Ma, J., Verweij, J., Kolker, H. J., Van Ingen, H. E., Stoter, G., Schellens, J. H.
The profiles of an i.v. bolus and 3 h and 20 h infusion of cisplatin (CDDP) were simulated in vitro by using a culture of the IGROV1 human ovarian cancer cell line. Disappearance of pharmacologically...
Klijn, J. G., Hoff, A. M., Planting, A. S., Verweij, J., Kok, T., Lamberts, S. W., ...
Somatostatin analogues can suppress the secretion of some gastrointestinal hormones and growth factors involved in the growth regulation of gastrointestinal cancers and can inhibit the growth of...
Verweij, J., Herweijer, H., Oosterom, R., Van Der Burg, M. E., Planting, A. S., Seynaeve, C., ...
We determined the ability of the multidrug resistance (MDR) reversal agent cyclosporin-A to increase anthracycline drug accumulation in colorectal tumour cells in vitro, using the technique of...
Sulkes, A., Smyth, J., Sessa, C., Dirix, L. Y., Vermorken, J. B., Kaye, S., ...
Thirty-seven eligible patients, median age 59 years (range 37-72) and median performance status 1 (0-2), with advanced, untreated, measurable gastric carcinoma were given docetaxel, 100 mg m-2 i.v....
Ma, J., Verweij, J., Planting, A. S., Van Ingen, H. E., Van Der Burg, M. E., ...
DNA adduct levels were measured with atomic spectroscopy in white blood cells (WBCs) from patients with solid tumours who were treated with six weekly courses of cisplatin. In 21 patients (I) the...
De Wit, R., Kruit, W. H., Stoter, G., De Boer, M., Kerger, J., Verweij, J.
The semisynthetic taxoid docetaxel was investigated in a phase II study in non-chemotherapy pretreated patients with metastatic urothelial cell cancer. Thirty patients (median age 61, range 45-72)...
Nielsen, O. S., Dombernowsky, P., Mouridsen, H., Crowther, D., Verweij, J., Buesa, J., ...
The activity and toxicity of single-agent standard-dose doxorubicin were compared with that of two schedules of high-dose epirubicin. A total of 334 chemonaive patients with histologically confirmed...
Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
Hilkens, P. H., Pronk, L. C., Verweij, J., Vecht, C. J., Van Putten, W. L., Van Den Bent, M. J.
Docetaxel, a new semisynthetic taxoid that has demonstrated promising activity as an antineoplastic agent, was administered in combination with cisplatin to 63 patients in a dose-escalating study. As...
Gerrits, C. J., Creemers, G. J., Schellens, J. H., Wissel, P., Planting, A. S., Kunka, R., ...
Topoisomerase I inhibitors are interesting anti-cancer agents with a novel mechanism of action. We performed a phase I study with intravenous GI147211, a new semisynthetic camptothecin analogue,...
Hanauske, A. R., Catimel, G., Aamdal, S., Paridaens, R., Pavlidis, N., ...
Rhizoxin is a new anti-tumour agent isolated from the pathogenic fungus Rhizopus chinensis. It has shown broad activity against murine tumour models and is also active against vinca...
Verweij, J., Wanders, J., Gil, T., Schöffski, P., Catimel, G., Te Velde, A., ...
To test the anti-tumour activity of rhizoxin in recurrent and/or metastatic squamous cell head and neck cancer, we performed a phase II study. Eligibility required histologically proven squamous cell...
Kaplan, S., Hanauske, A. R., Pavlidis, N., Bruntsch, U., Te Velde, A., Wanders, J., ...
In a multicentre trial of the EORTC-Early Clinical Trials Group (ECTG) we treated 31 chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) with rhizoxin, a novel...
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
Schellens, J. H., Creemers, G. J., Beijnen, J. H., Rosing, H., McDonald, M., ...
The results of preclinical and clinical studies indicate enhanced antineoplastic activity of topotecan (SKF 104864-A) when administered as a chronic treatment. We determined the apparent...
Planting, A. S., Van Der Burg, M. E., Van Den Bent, M. J., Stoter, G., Verweij, J.
In a phase I study of weekly administered cisplatin combined with oral etoposide, we observed a partial response in 4 out of 11 patients with metastatic colorectal cancer. Subsequently, we performed...
Schellens, J. H., Ma, J., Planting, A. S., Van Der Burg, M. E., Van Meerten, E., ...
The study was designed to investigate possible relationships between tumour response and exposure to cisplatin (area under the curve of unbound cisplatin in plasma, AUC) and DNA-adduct formation in...
De Wit, R., Beijnen, J. H., Van Tellingen, O., Schellens, J. H., Verweij, J.
We investigated the pharmacokinetic profile and the efficacy of ondansetron (day 1) given as 16 mg suppository once a day, as compared with ondansetron 8 mg tablets twice daily, in patients receiving...
Goey, S. H., Gratama, J. W., Primrose, J. N., Ward, U., Mertelsmann, R. H., Osterwalder, B., ...
Treatment using a combination of 5-fluorouracil (5-FU), interferon-alpha (IFN alpha-2a) and interleukin 2 (IL-2) has been shown to mediate disease regression in selected patients with advanced...
McLeod, H. L., Murray, L. S., Wanders, J., Setanoians, A., Graham, M. A., Pavlidis, N., ...
Rhizoxin is a macrocyclic lactone compound that binds to tubulin and inhibits microtubule assembly. Rhizoxin demonstrated preclinical anti-tumour activity against a variety of human tumour cell lines...
Ma, J., Maliepaard, M., Nooter, K., Loos, W. J., Kolker, H. J., Verweij, J., ...
In order to unravel possible mechanisms of clinical resistance to topoisomerase I inhibitors, we developed a topotecan-resistant human IGROV-1 ovarian cancer cell line, denoted IGROV(T100r), by...
De Wit, R., Burghouts, J., Nortier, J., Slee, P., Rodenburg, C., ...
We have reported previously that the anti-emetic efficacy of single agent 5HT3 antagonists is not maintained when analysed with the measurement of cumulative probabilities. Presently, the most...
De Wit, R., Kruit, W. H., Lamers, C. H., Van 't Veer, M. B., Luyten, A. A., Van Beurden, V., ...
We investigated the reconstitutive potential of haematopoietic progenitor cells collected in autologous whole blood during multicycle dose-intensified chemotherapy. Forty patients with metastatic...
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
Pronk, L. C., Schrijvers, D., Schellens, J. H., De Bruijn, E. A., Planting, A. S., Locci-Tonelli, D., ...
Docetaxel and ifosfamide have shown significant activity against a variety of solid tumours. This prompted a phase I trial on the combination of these drugs. This phase I study was performed to...
Bakker, M., Droz, J. P., Hanauske, A. R., Verweij, J., Van Oosterom, A. T., Groen, H. J., ...
The aim was to perform a broad phase II and pharmacokinetic study of methoxymorpholino-doxorubicin (MMRDX), a drug active against multidrug-resistant tumour cells in vitro when given by i.v. bolus at...
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
Gerrits, C. J., Schellens, J. H., Creemers, G. J., Wissel, P., Planting, A. S., Pritchard, J. F., ...
Topoisomerase I inhibitors are new compounds of interest for cancer chemotherapy. We performed a study with GI147211, a new semisynthetic camptothecin analogue, to determine the absolute...
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists.
De Wit, R., Schmitz, P. I., Djontono, J., V Beurden, V., Stoter, G., ...
In 1983, Coates conducted a survey that ranked the side-effects perceived by patients receiving chemotherapy in the order of their severity. Vomiting and nausea were found to be the two most...
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
Gerrits, C. J., De Jonge, M. J., Schellens, J. H., Stoter, G., Verweij, J.
Topoisomerase I inhibitors constitute a new class of anti-cancer agents. Recently, topotecan and irinotecan were registered for clinical use in ovarian cancer and colorectal cancer respectively....
Mom, C H, Planting, A S T, Gietema, J A, Amelsberg, A, Huisman, H, ...
To assess tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of the dual epidermal growth factor receptor (EGFR) 1 and 2 (HER2) tyrosine kinase inhibitor BIBW 2992. An...
Attard, G, Kitzen, J, Blagden, S P, Fong, P C, Pronk, L C, Zhi, J, ...
Pertuzumab represents the first in a new class of targeted therapeutics known as HER dimerisation inhibitors. We conducted a phase Ib study to determine the maximum-tolerated dose, the dose limiting...
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review
Engels, F K, Sparreboom, A, Mathot, R A A, Verweij, J
Since the introduction of docetaxel, research has focused on various approaches to overcome treatment limitations and improve outcome. This review discusses the pharmacological attempts at treatment...
Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule
Awada, A, Punt, C J A, Piccart, M J, Tellingen, O Van, Manen, L Van, Kerger, J, ...
Carzelesin is a cyclopropylpyrroloindole analogue which acts as a DNA-sequence-specific alkylating agent. In this phase I study, Carzelesin was given as a 4-weekly 10 min IV infusion to 51 patients...
Fokkema, E, Verweij, J, Van Oosterom, A T, Uges, D R A, Spinelli, R, Valota, O, ...
The aim of this phase I study was to assess feasibility, pharmacokinetics and toxicity of methoxymorpholino doxorubicin (MMRDX or PNU-152243) administered as a 3 h intravenous infusion once every 4...
Pronk, L C, Vasey, P, Sparreboom, A, Reigner, B, Planting, A S Th, Gordon, R J, ...
Capecitabine and docetaxel are both active against a variety of solid tumours, while their toxicity profiles only partly overlap. This phase I study was performed to determine the maximum tolerated...
Gelderblom, H, Sparreboom, A, Loos, W J, Wilms, E, Mantel, M A, ...
Both weekly cisplatin chemotherapy and single agent topotecan have proven to be effective in recurrent ovarian cancer. Preclinical data show synergism between cisplatin and topotecan. Side effects...
De Wit, R, De Boer, A C, Stoter, G, Sparreboom, A, Verweij, J
In view of the similarity in chemical structure of the available 5HT3-receptor antagonists it is assumed, whilst these agents all act at the same receptor, that failure to one agent would predict...
Polee, M B, Splinter, T A W, Siersema, P D, Tilanus, H W, ...
In a phase I study we demonstrated the feasibility of a bi-weekly combination of paclitaxel 180 mg m−2 with cisplatin 60 mg m−2. In this study we further assessed toxicity and efficacy of...
Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38
Mathijssen, R H J, Verweij, J, Loos, W J, De Bruijn, P, Nooter, K, Sparreboom, A
We have shown previously that the terminal disposition half-life of SN-38, the active metabolite of irinotecan, is much longer than earlier thought. Currently, it is not known whether this prolonged...
Factors affecting pharmacokinetic variability of oral topotecan: a population analysis
Léger, F, Loos, W J, Fourcade, J, Bugat, R, Goffinet, M, Mathijssen, R H J, ...
Kaye, S, Verweij, J, Brock, C, Reade, S, Scurr, M, ...
Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
De Wit, R, Logmans, A, Kruit, W H J, Stoter, G, ...
We investigated the potential of weekly cisplatin and daily oral etoposide followed by oral etoposide maintenance therapy in patients with platinum-refractory ovarium cancer. One hundred and seven...
Reply: Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?
De Wit, R, Stoter, G, Sparreboom, A, Verweij, J, De Boer, A C
British Journal of Cancer (2002) 86, 1664–1664. DOI: 10.1038/sj/bjc/6600314 www.bjcancer.com
De Jongh, F E, Van Veen, R N, Veltman, S J, De Wit, R, Van Den Bent, M J, ...
In the present study we describe the toxicity of weekly high-dose (70–85 mg m−2) cisplatin in 400 patients (203 men, 197 women; median age 54 years) with advanced solid tumours treated in the...